Literature DB >> 18156303

Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer.

Arzu Yaren1, Ilhan Oztop, Sebahat Turgut, Gunfer Turgut, Serkan Degirmencioglu, Mustafa Demirpence.   

Abstract

The angiotensin-converting enzyme (ACE) plays an important role not only in the regulation of vascular homeostasis but also in stimulation of hematopoiesis. We aimed to evaluate the association between insertion/deletion (I/D) polymorphism of the ACE gene and anemia at the time of the diagnosis. We enrolled 75 patients with non-small-cell lung cancer (NSCLC) and 85 age- and sex-matched healthy control participants. The I/D polymorphism of ACE was identified by using polymerase chain reaction from peripheral blood samples. Statistical analyses were performed with SPSS for Windows. The distributions of the ACE genotypes and alleles are similar in patients and in healthy participants (P=0.29 and P=0.08, respectively). In patients with NSCLC, 34 (45.3%) had anemia; of whom 3 (8.8%) had genotype II, 24 (70.6%) had genotype ID, and 7 (20.6%) had genotype DD (P=0.001). The patients with the II and ID genotypes had more frequent anemia at the time of the diagnosis (odds ratio = 6.02; P=0.001). Our findings suggest that I/D polymorphism of the ACE gene may influence the development of anemia in patients with NSCLC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18156303     DOI: 10.3181/0705-RM-141

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  8 in total

1.  RETRACTED: Association of Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism With Lung Cancer Susceptibility.

Authors:  Xiao-Neng Mo; Ri-Wen Yang; Feng Zhang; Yu Dong; Zi-Wen Zhao
Journal:  Technol Cancer Res Treat       Date:  2016-06-23

Review 2.  Association between angiotensin I-converting enzyme gene polymorphism and susceptibility to cancer: a meta analysis.

Authors:  Kan Zhang; Dan Cheng; Lingling Yi; Huimin Shi; Guohua Zhen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  The insertion/deletion (I/D) polymorphism in the Angiotensin-converting enzyme gene and cancer risk: a meta-analysis.

Authors:  Yonggang Zhang; Jie He; Yao Deng; Jie Zhang; Xiaobo Li; Zhangpeng Xiang; Honglang Huang; Can Tian; Jin Huang; Hong Fan
Journal:  BMC Med Genet       Date:  2011-12-12       Impact factor: 2.103

4.  Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China.

Authors:  Xiao Wang; Shuai Wang; Yi-wei Lin; Jian Wu; Hong Chen; Ye-qing Mao; Xiang-yi Zheng; Cheng Zhou; Li-ping Xie
Journal:  Med Oncol       Date:  2011-08-28       Impact factor: 3.064

5.  An updated meta-analysis on association between angiotensin I-converting enzyme gene insertion/deletion polymorphism and cancer risk.

Authors:  Yuebing Xie; Chao You; Jing Chen
Journal:  Tumour Biol       Date:  2014-04-03

6.  Association of angiotensin-converting enzyme gene insertion/deletion polymorphism and obstructive sleep apnoea in a Chinese population: A meta-analysis.

Authors:  Jian Xu; Jiming Chen; Yilu Li; Dandan Zhang; Xiaoli Li
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020-06-17       Impact factor: 1.636

7.  The influence of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications.

Authors:  Konstantinos I Papadopoulos; Warachaya Sutheesophon; Tar-Choon Aw
Journal:  Chem Biol Interact       Date:  2022-01-26       Impact factor: 5.192

8.  Influence of ACE I/D Polymorphism on Circulating Levels of Plasminogen Activator Inhibitor 1, D-Dimer, Ultrasensitive C-Reactive Protein and Transforming Growth Factor β1 in Patients Undergoing Hemodialysis.

Authors:  Sara Santos de Carvalho; Ana Cristina Simões e Silva; Adriano de Paula Sabino; Fernanda Cristina Gontijo Evangelista; Karina Braga Gomes; Luci Maria SantAna Dusse; Danyelle Romana Alves Rios
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.